Literature DB >> 26728737

Far-red fluorescent cell line for preclinical study of HER2-targeted agents.

I V Balalaeva1,2, E A Sokolova3,4, A A Brilkina3,4, S M Deyev3,4, R V Petrov3,4.   

Abstract

We have created novel HER2-overexpressing human ovarian adenocarcinoma cell line stably transfected with far-red fluorescent protein TurboFP635. Growth characteristics, adhesion capacity and morphology of the cells do not differ from that of parental cell line. The obtained cell line (SKOV-kat) was confirmed to have high level of expression of the tumor marker HER2 comparable to that of initial cell line SKOV-3. The SKOV-kat cell line is designed for further establishment of experimental fluorescent models of HER2-overexpressing human ovarian cancer that make it possible to optimize and reduce the cost of preclinical study of agents for treatment of this disease.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26728737     DOI： 10.1134/S1607672915060174

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


  14 in total

1.  Bright far-red fluorescent protein for whole-body imaging.

Authors:  Dmitry Shcherbo; Ekaterina M Merzlyak; Tatiana V Chepurnykh; Arkady F Fradkov; Galina V Ermakova; Elena A Solovieva; Konstantin A Lukyanov; Ekaterina A Bogdanova; Andrey G Zaraisky; Sergey Lukyanov; Dmitriy M Chudakov
Journal:  Nat Methods       Date:  2007-08-26       Impact factor: 28.547

2.  Cytotoxic effect of the immunotoxin constructed of the ribosome-inactivating protein curcin and the monoclonal antibody against Her2 receptor on tumor cells.

Authors:  Lidia Patricia Jaramillo-Quintero; Arturo Contis Montes de Oca; Andrés Romero Rojas; Saúl Rojas-Hernández; Rafael Campos-Rodríguez; Alma Leticia Martínez-Ayala
Journal:  Biosci Biotechnol Biochem       Date:  2015-02-23       Impact factor: 2.043

3.  High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer.

Authors:  Michael Bouvet; Joseph Spernyak; Matthew H Katz; Richard V Mazurchuk; Shinako Takimoto; Ralph Bernacki; Youcef M Rustum; Abdool R Moossa; Robert M Hoffman
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  Imaging the inhibition by anti-β1 integrin antibody of lung seeding of single osteosarcoma cells in live mice.

Authors:  Hiroaki Kimura; Yasunori Tome; Masashi Momiyama; Katsuhiro Hayashi; Hiroyuki Tsuchiya; Michael Bouvet; Robert M Hoffman
Journal:  Int J Cancer       Date:  2012-03-14       Impact factor: 7.396

Review 5.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

6.  Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications.

Authors:  Nikolaos C Deliolanis; Randa Kasmieh; Thomas Wurdinger; Bakhos A Tannous; Khalid Shah; Vasilis Ntziachristos
Journal:  J Biomed Opt       Date:  2008 Jul-Aug       Impact factor: 3.170

Review 7.  Targeting HER2 in ovarian and uterine cancers: challenges and future directions.

Authors:  Eleonora Teplinsky; Franco Muggia
Journal:  Gynecol Oncol       Date:  2014-09-16       Impact factor: 5.482

8.  Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.

Authors:  E A Sokolova; T A Zdobnova; O A Stremovskiy; I V Balalaeva; S M Deyev
Journal:  Biochemistry (Mosc)       Date:  2014-12       Impact factor: 2.824

9.  In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.

Authors:  Alessa Pardo; Michael Stöcker; Florian Kampmeier; Georg Melmer; Rainer Fischer; Theo Thepen; Stefan Barth
Journal:  Cancer Immunol Immunother       Date:  2012-02-19       Impact factor: 6.630

10.  Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.

Authors:  Kristina E Mironova; Galina M Proshkina; Anastasiya V Ryabova; Oleg A Stremovskiy; Sergey A Lukyanov; Rem V Petrov; Sergey M Deyev
Journal:  Theranostics       Date:  2013-10-12       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.